Advertisement

Journal of Endocrinological Investigation

, Volume 27, Issue 3, pp 259–264 | Cite as

Effects of Graves’ ophthalmopathy on quality of life

  • W. M. Wiersinga
  • M. F. Prummel
  • C. B. Terwee
Article

Abstract

General health-related quality of life is markedly impaired in patients with Graves’ ophthalmopathy (GO), and even worse than in patients with other chronic conditions like diabetes, emphysema or heart failure. A disease-specific quality-oflife questionnaire for GO has been developed, the so-called GO-QOL, consisting of two subscales: one for visual functioning (8 questions referring to limitations due to decreased visual acuity and/or diplopia) and one for appearance (8 questions referring to limitations in psychosocial functioning due to changes in appearance). The GO-QOL was found to be a valid and reliable instrument. A minimal clinically important difference (MCID) in the GO-QOL score was derived from data obtained before and after specific eye treatments. Based on the patient’s opinions, changes of ≥ 6 points (minor surgery) or ≥ 10 points (surgical decompression, immunosuppression) are recommended as MCID. It is concluded that the GO-QOL is an useful instrument for measuring changes over time in visual functioning and appearance of GO patients. The GO-QOL is available in six languages, and can be used as a separate outcome measure in clinical studies.

Key-words

Graves’ ophthalmopathy quality of life GO-QOL 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Terwee CB. Graves’ ophthalmopathy through the eyes of the patient. Assessment of health-related quality of life. Ph.D. Thesis, University of Amsterdam, 2000.Google Scholar
  2. 2.
    Campbell A, Converse PE, Rodgers WL. The quality of American life. New York: Sage. 1976Google Scholar
  3. 3.
    Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996, 334: 835–40PubMedCrossRefGoogle Scholar
  4. 4.
    Prummel MF, Mourits MPh, Blank L, et al. Randomized double- blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 1993, 342: 949–54PubMedCrossRefGoogle Scholar
  5. 5.
    Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. JAMA 1995, 273: 59–65PubMedCrossRefGoogle Scholar
  6. 6.
    Guyatt GH, Naylor D, Juniper E, et al. User’s guides to the medical literature. XII. How to use articles about health-related quality of life? JAMA 1997, 277: 1232–7PubMedCrossRefGoogle Scholar
  7. 7.
    Pinchera A, Wiersinga WM, Glinoer D, et al. Classification of eye changes of Graves’ disease. Thyroid 1992, 2: 235–6CrossRefGoogle Scholar
  8. 8.
    Prummel MF, Mourits MPh, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N Engl J Med 1989, 321: 1353–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Kahn JA, Doane JF, Whitacre MM. Does compression diminish the discomfort of severe dysthyroid orbitopathy? Ophthalm Plast Reconstruct Surg 1995, 11: 109–12CrossRefGoogle Scholar
  10. 10.
    Kung AWC, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroid in the treatment of Graves’ ophthalmopathy. Thyroid 1996, 6: 381–4PubMedCrossRefGoogle Scholar
  11. 11.
    Fatourechi V, Garrity JA, Bartley GB, Bergstrahl EJ, DeSanto LW, Gorman CA. Results of transantral orbital decompression performed primarily for cosmetic indications. Ophthalmology 1994, 101: 938–42PubMedCrossRefGoogle Scholar
  12. 12.
    Kane RL, Maciesjewski M, Finch M. The relationship of patient satisfaction with care and clinical outcomes. Med Care 1997, 35: 714–30PubMedCrossRefGoogle Scholar
  13. 13.
    Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30: 473–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Aaronson NK, Muller M, Cohen PDA, et al. Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol 1998, 51: 1055–68.PubMedCrossRefGoogle Scholar
  15. 15.
    Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study instrument. Thyroid 1997, 7: 885–9PubMedCrossRefGoogle Scholar
  16. 16.
    Stewart AL, Greenfield S, Wells K, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989, 262: 907–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Kahaly GJ, Hardt J, Petrak F, Egle UT. Psychosocial factors in subjects with thyroid-associated ophthalmopathy. Thyroid 2002, 12: 237–39PubMedCrossRefGoogle Scholar
  18. 18.
    Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease-specific quality of life questionnaire for patients with Graves’ ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998, 82: 773–9PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Terwee CB, Gerding MN, Dekker FW, Prummel MF, van der Pol JP, Wiersinga WM. Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves’ ophthalmopathy. J Clin Epidemiol 1999, 52: 875–84PubMedCrossRefGoogle Scholar
  20. 20.
    Terwee CB, Dekker FW, Mourits MPh, et al. Interpretation and validity of changes in scores in the GO-QOL after different treatments. Clin Endocrinol (Oxf) 2001, 54: 391–8CrossRefGoogle Scholar
  21. 21.
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clin Trials 1989, 10: 407–15PubMedCrossRefGoogle Scholar
  22. 22.
    Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow- up of Graves’ ophthalmopathy in an incidence cohort. Ophthalmopathy 1996, 103: 958–62CrossRefGoogle Scholar
  23. 23.
    Terwee CB, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga WM. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol 2002, 146: 751–7PubMedCrossRefGoogle Scholar
  24. 24.
    Sprangers MAG, de Regt EB, Andries F, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol 2000, 53: 895–907PubMedCrossRefGoogle Scholar
  25. 25.
    Fayers P, Bjordal K. Should quality-of-life needs influence resource allocation? Lancet 2001, 357: 978PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2004

Authors and Affiliations

  • W. M. Wiersinga
    • 1
  • M. F. Prummel
    • 1
  • C. B. Terwee
    • 2
  1. 1.Department of Endocrinology and MetabolismAmsterdamThe Netherlands
  2. 2.Institute for Research in Extramural MedicineVU University Medical CenterAmsterdamThe Netherlands

Personalised recommendations